AstraZeneca: AZD1222 vaccine met primary efficacy in preventing COVID-19

Today marks an important step in turning the corner on the coronavirus pandemic and getting things back to normal.

Following the positive high-level results from an interim analysis of clinical trials of AZD1222 in the United Kingdom and Brazil, which showed the vaccine was effective in preventing COVID-19,

AstraZeneca’s Country President, African Cluster, Barbara Nel, said,

“We are confident that our united response, across the scientific community, industry, organisations, and governments, will make significant inroads in curbing the COVID-19 pandemic that has continued to claim thousands of lives every day in Africa and across the globe.

“We will continue to work hard to honour our commitment to make the vaccine available in a fair and equitable manner as rapidly as possible, following robust regulatory approval and meeting stringent efficacy and safety standards. It is a great day for innovation and for inclusion, an exciting moment for human health.”

Get in Touch

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles